There aren't many biotechs that are more exciting than Viking Therapeutics (NASDAQ: VKTX) right now. Thanks to its ...

Investors with a lot of money to spend have taken a bullish stance on Viking Therapeutics VKTX. And retail traders should ...

Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid ...

On Friday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $49.58 which represents a decrease of $-3.99 or -7.45% from the prior close of $53.57. The stock opened at $53.18 and ...

So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Viking Therapeutics (NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of today's highest-growth healthcare markets: weight loss drugs. The biotech ...

Viking aims to compete against market giants Eli Lilly and Novo Nordisk in the billion-dollar weight loss drug market. The biotech recently revealed promising data from trials of its oral weight ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $13.97.Don't Miss our ...